Acute ischaemic stroke associated secondary infection with rhino-orbital cerebral mucormycosis associated with covid-19 with beta thalassaemia trait

Coronavirus disease 2019 (COVID-19) 1st emerged in Wuhan, China in December 2019, and since then the frequency of bacterial and fungal coinfections has been continuously rising. While invasive pulmonary aspergillosis is increasingly being recognized in association with COVID-19, there is limited information with regards to COVID-19 associated mucormycosis. During the current pandemic of COVID-19, a myriad of manifestations and complications has emerged and are being reported on. We are discovering patients with COVID-19 are at increased risk of acute cardiac injury, arrythmias, thromboembolic complications (pulmonary embolism and acute stroke), and secondary infection to name a few. In this article we describe a novel case of COVID-19 in a who presented for altered mental status and proptosis. She was ultimately diagnosed with mucormycosis and orbital compartment syndrome, in addition to COVID-19. Early identification of these high morbidity conditions is key to allow for optimal treatment and improved outcomes.due to facial swelling and numbness,and a diagnosis of COVID-19 associated rhinosinusitis mucormycosis due to Rhizopusoryzae was conrmed with PCR and DNA sequencing. This report aims to address the importance of short-term follow-up in COVID-19 patients who have received systemic corticosteroids, particularly those with predisposing conditions, as early detection and prompt, aggressive treatment is essential for the management of invasive fungal infections.